- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Development of RNA aptamers for therapeutics
-
- Miyakawa Shin
- RIBOMIC Inc.
-
- Fujiwara Masatoshi
- RIBOMIC Inc.
-
- Nishiyama Michihisa
- RIBOMIC Inc.
Bibliographic Information
- Other Title
-
- バイオ素材による創薬とDDS RNAアプタマーを用いた分子標的医薬の開発
- RNAアプタマーを用いた分子標的医薬の開発
- RNA アプタマー オ モチイタ ブンシ ヒョウテキ イヤク ノ カイハツ
Search this article
Description
In recent years, RNA aptamers have been regarded as the next generation of antibody therapeutic drugs. RNA aptamers are selected by in vitro selection referred to as SELEX and after going through truncation and modification, they become candidates for therapeutic drugs. PEGylation is used for substantial improvement of pharmacokinetics. An aptamer itself is potentially a therapeutic drug, but it can also be used as a drug delivery agent by conjugating it with an agent such as an anti-cancer agent. In this review, developmental processes and typical properties of aptamer therapeutic drugs will be reviewed. vWF aptamer, which is now in phase II clinical studies, and MK aptamer, which is being developed by RIBOMIC Inc., will be also reviewed.
Journal
-
- Drug Delivery System
-
Drug Delivery System 23 (5), 534-543, 2008
THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001204640534144
-
- NII Article ID
- 10024309954
-
- NII Book ID
- AN10084591
-
- COI
- 1:CAS:528:DC%2BD1cXhtleisbnL
-
- ISSN
- 18812732
- 09135006
-
- NDL BIB ID
- 9661680
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL Search
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed